简介：AbstractObjective:Irreversible electroporation (IRE) is emerging as a new therapy for locally advanced pancreatic cancer (LAPC). We aimed to conduct survival and safety analyses in LAPC patients after treatment with IRE combined with chemotherapy.Methods:A total of 64 patients with LAPC who had received IRE and chemotherapy were retrospectively collected from August 2015 to March 2019 at Sun Yat-sen University Cancer Center. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier method and compared by the log-rank test. A multivariate Cox regression model was used to determine the prognostic factors of survival. The perioperative complications of IRE were also evaluated. The study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center (approval No. C2021-003).Results:The median survival of all included patients were 24.63 (95% confidence interval: 21.78-27.49) for overall survival and 13.00 (95% confidence interval: 8.81-17.19) months for progression-free survival, with 96.8%, 51.9%, 18.3%; and 52.3%, 21.5%, 7.9% as the 1-, 2-and 3-year OS and PFS rates, respectively. Tumor size [OS, hazard ratio (HR)=1.768, P= 0.048; PFS, HR= 0.304, P= 0.010], neoadjuvant chemotherapy (OS, HR= 0.338, P= 0.030; PFS, HR= 0.358, P= 0.034), carbohydrate antigen 19-9 variation after IRE (OS, HR= 19.320, P= 0.003; PFS, HR= 14.591, P= 0.021) and tumor response after neoadjuvant chemotherapy (OS, HR= 8.779, P= 0.033; PFS, HR= 5.562, P= 0.008) were predictive factors of survival in patients with LAPC after IRE. Complications were observed in 20.3% of patients. Grade B pancreatic fistula was the most common complication. The complication rates of the late treatment group (6.1%) were significantly lower than those of the first 15 patients after IRE treatment (66.7%). The median length of hospital stay of late treatment group was 8.6 days, which was also shorter than that of the early treatment group (10.0 days).Conclusions:IRE combined with chemotherapy could improve survival of LAPC patients with acceptable complication rates. Therefore, it may be a suitable method for LAPC but should be validated in prospective randomized trials.

简介：Objective:Epidermalgrowthfactorreceptor(EGFR)activationwasreportedtoupregulateprogrammeddeath-ligand1(PD-L1)expressioninlungcancercellsandsubsequentlycontributetoimmuneescape,indicatingitscriticalroleinEGFR-drivenlungtumors.ThisstudycharacterizedPD-L1expressioninpatientswithsurgicallyresectedEGFR-mutantnon-smallcelllungcancer(NSCLC).TheeffectofPD-L1expressiononclinicaloutcomeswasalsoinvestigatedinadvancedEGFR-mutantNSCLCtreatedwithEGFR-tyrosinekinaseinhibitors(TKIs).Methods:Intotal,73patientswithsurgicallyresectedNSCLCandEGFRmutationswereidentified.PD-L1expressionandCD8+tumor-infiltratinglymphocyte(TIL)densitywereassessedbyimmunohistochemistry.AliteraturereviewofpublicationsthatassessedthepredictiveandprognosticvalueofPD-L1expressioninadvancedEGFR-mutantNSCLCpatientstreatedwithEGFRTKIswasperformed.Results:Nineteen(26.0%)patientswerepositiveforPD-L1expression,whichwassignificantlyassociatedwithconcomitantKRASmutation(P=0.020)andmarginallyassociatedwithhigherCD8+TILsdensity(P=0.056).PositivePD-L1expressionwasassociatedwithmarkedlyinferioroverallsurvival(OS)inmultivariateanalysis(P=0.032).ThecombinationofPD-L1andCD8+TILsexpressioncouldbeusedtostratifythepopulationintothreegroupswithdistinctprognoses.Ameta-analysisofsixpublicationsshowedthatpositivePD-L1expressionwasnotassociatedwithOS[hazardratio(HR)=0.90;95%confidenceinterval(CI),0.42–1.38]orprogression-freesurvival(HR=1.03;95CI,0.73–1.33)inadvancedEGFR-mutantNSCLCpatientsreceivingEGFR-TKIs.Conclusions:PD-L1expressiontendedtocorrelatewithCD8+TILexpression,concomitantKRASmutation,andpoorsurvivalinsurgicallyresectedEGFR-mutantNSCLC.PD-L1expressionwasneitherthepredictivenortheprognosticfactorinadvancedEGFR-mutantNSCLCpatientstreatedwithEGFR-TKIs.

简介：Purpose:Wntpathwayscontrolkeybiologicalprocessesthatpotentiallyimpactontumorprogressionandpatientsurvival.Thepresentstudyanalyzedthepolymorphismoflipoprotein-relatedreceptor5(LRP5)(genewithkeyfunctionsinWntsignaling)anditsimpactontheresponsetochemotherapyandsurvivalofpatientswithadvancedgastriccancer(AGC).Methods:Atotalof107consecutivepatientswithAGCtreatedwithfirst-linechemotherapyofEOFregimenwereenrolledinthepresentretrospectivestudy.Theassociationbetweensinglenucleotidepolymorphism(SNP)ofrs3736228inLRP5andtheclinicaloutcomesofthepatientswasstudied.Results:TheCCgenotypeofrs3736228wassignificantlycorrelatedwithahigherdiseasecontrolratewhencomparedtotheCTandTTgenotypes(89.3%and61.8%,respectively,P<0.001).Aunivariatesurvivalanalysisalsoshowedthattheprogressionfreesurvival(PFS)andoverallsurvival(OS)forthepatientswiththeTCandTTgenotypesofrs3736228wereworsethanforthepatientswiththeCCgenotype(PFS:3.3and6.7months,respectively,HR=0.454,P<0.001;OS:8.1monthsand18.8months,respectively,HR=3.056,P<0.001).AmultivariateCoxmodelincorporatesrs3736228andclinicalfeatures,alsoidentifiedrs3736228wassignificantlyassociatedwiththePFSandOS.Conclusions:OurresultsfirstlyhighlighttheimportanceofLRP5geneofWntpathwayinthetreatmentofAGCandidentifypolymorphismofrs3736228asindependentpredictorofdiseasecontrolrate,PFSandOSinAGCpatientstreatedwithfirst-linechemotherapyofEOFregimenintheChineseHanpopulation.

简介：瞄准：估计他我在勃起组织ofsildenafil的oxygenase-1(HO-1)活动对待柠檬酸盐的老鼠。方法：192只Sprague-Dawley雄的老鼠，划分了成四个相等的组，被调查。组织1，控制组，收到的常规动物食物；由胃内试管组织2收到的sildenafil柠檬酸盐；组3收到的sildenafiland惊讶禁止者(锌原卟啉，ZnPP)；并且组4收到了sildenafil和氮的oxidesynthase(NOS)禁止者L-nitroarginine甲基酉旨(L名字)。从每个组的12只老鼠在0.5h，1h，2h和药管理的3h以后被打死。然后，在勃起组织的HO-1活动，cGMP层次和NOSenzymatic活动被估计。结果：在勃起组织，HO-1activity，NOS酶的活动和cGMP，集中在整个实验与另外的组相比增加了显著地对待insildenafil的老鼠。收到任何一个HOorNOS禁止者的老鼠在这些参数显示出重要减少。酶的活动表明了的HO-1勃起组织活动和NOS与cGMP层次的积极重要关联(r=0.646，r=0.612分别地；P<0.001)。结论：在勃起组织的PDE_5禁止者sildenafilcitrate的行动部分通过在HO-1和NOS活动之间的相互依赖的关系被调停。

简介：

简介：Migraineisaneurovascularheadachewithrecurrentattackandlonghistory.Itisquitedifficultinclinicforthehealingofmigraine.Theauthorsince1993,hastreatedmigraineurswithpoint-injection,acupuncturecombinedwithChineseherbsinspecialmigraineclinicofZhejiang

简介：AbstractWide-awake local anesthesia has many advantages. We describe a new method to use wide-awake local anesthesia with more flexibility. A 32-year-old man with a severe right-hand contracture after an iatrogenic tourniquet accident during an anterolateral thigh flap for a partial hand amputation underwent contracture release using external fixation after proximal row carpectomy and subsequent tenolysis. We performed most of the tenolysis procedure under general anesthesia and the final stage with an intra-operative assessment of active finger movement and dissection under local anesthesia. He regained his grip strength 2.5 years post-injury. General anesthesia is useful to treat a surgical site with extensive hard scars, whereas local anesthesia is useful for adjusting tension in an awake patient. The indication for wide-awake surgery is yet to be established; our method of combining general and local anesthesia in the tenolysis procedure illustrates the possibilities in expanding this method.

简介：Sinee1988,theauthorhastreatedmi-grain。,namelyangioneurotieheadaehe,usinginjeetionoffleabaneinjeetiointoFengchi(GB20)andTaiyang(EX一HNS)pointswithasat-isfaetoryeffeet.ThiswasrePortedasfollows.GENERAL

简介：AbstractBackground:Although endovascular therapy has been widely used for focal aortoiliac occlusive disease (AIOD), its performance for extensive AIOD (EAIOD) is not fully evaluated. We aimed to demonstrate the long-term results of EAIOD treated by endovascular therapy and to identify the potential risk factors for the loss of primary patency.Methods:Between January 2008 and June 2018, patients with a clinical diagnosis of the 2007 TransAtlantic Inter-Society Consensus II (TASC II) C and D AIOD lesions who underwent endovascular treatment in our institution were enrolled. Demographic, diagnosis, procedure characteristics, and follow-up information were reviewed. Univariate analysis was used to identify the correlation between the variables and the primary patency. A multivariate logistic regression model was used to identify the independent risk factors associated with primary patency. Five- and 10-year primary and secondary patency, as well as survival rates, were calculated by Kaplan-Meier analysis.Results:A total of 148 patients underwent endovascular treatment in our center. Of these, 39.2% were classified as having TASC II C lesions and 60.8% as having TASC II D lesions. The technical success rate was 88.5%. The mean follow-up time was 79.2 ± 29.2 months. Primary and secondary patency was 82.1% and 89.4% at 5 years, and 74.8% and 83.1% at 10 years, respectively. The 5-year survival rate was 84.2%. Compared with patients without loss of primary patency, patients with this condition showed significant differences in age, TASC II classification, infrainguinal lesions, critical limb ischemia (CLI), and smoking. Multivariate logistic regression analysis showed age <61 years (adjusted odds ratio [aOR]: 6.47; 95% CI: 1.47-28.36; P = 0.01), CLI (aOR: 7.81; 95% CI: 1.92-31.89; P = 0.04), and smoking (aOR: 10.15; 95% CI: 2.79-36.90; P < 0.01) were independent risk factors for the loss of primary patency.Conclusions:Endovascular therapy was an effective treatment for EAIOD with encouraging patency and survival rate. Age <61 years, CLI, and smoking were independent risk factors for the loss of primary patency.

简介：

简介：ObjectivesTostudytheeffectsofbradykinin(BK)B2receptorblockadeoninfarctsizeandhemodynamicsaftermyocardialinfarction(MI)inratswithangiotensin-convertingenzyme(ACE)inhibitiontherapy.MethodsMIwasproducedbyligatingtheleftcoronaryartery.Theeffectsofenalapril(500μg/kg·day),enalapril(500μg/kg·day)withBKB2receptorantagonistHoe-140(500μg/kg·day),angiotensinII(AngII)type1(AT1)receptorantagonistlosartan(3mg/kg·day)oninfarctsize,leftventricularsystolicpressure(LVSP),cardiacoutputindex(CI)andstrokevolumeindex(SVI)wereobservedinratsafterMI.Treatmentswerestartedonthe2nddayafterMIandcontinuedforanother6weeks.ResultsEnalaprilreducedinfarctsizeandimprovedCIandSVIcomparedwiththeuntreatedMIgroup(P<0.05),andtheseeffectsofenalaprilweresignificantlybluntedbyconcomitanttreatmentwithHoe-140(P<0.05).Losartanwaslesseffectivethanenalapril.LVSPwereunchangedinthethreetreatmentgroups.ConclusionsBKcanreduceinfractsizeandimprovehemodynamicsinratsfollowingMI.ThecardioprotectiveeffectsofACEIpartlyresultfromtheactionofBKexertedthroughtheB2receptor.

简介：Abiraterone醋酸盐为阉割抵抗的前列腺癌症(CRPC)的治疗被同意；然而，它的效果变化。识别将得益于abiraterone治疗的耐心的组的一个精确预言模特儿着急地因此被要求。迟模型为风险分类展出好侧面，尽管它为化疗天真的组的用途是不清楚的。这研究试图外部地验证迟模型并且开发一张新诺模图预言全面幸存(OS)。我们回顾地分析了110个病人的一个队。病人们被散布在之中好--，中间--，并且差风险的组，根据迟模型的意见。好--，中间--，并且差风险的组有59的一种样品尺寸(53.6%)，34(30.9%)，并且17(15.5%)在我们的数据集，和48.4，29.1，和10.5个月的中部的OS分别地。迟模型的外部确认的C索引是0.726。Univariate和multivariate分析识别了低血红素集中(<110gl1),肝转移，和到abiraterone开始的从雄激素剥夺治疗的短时间间隔(<36个月)作为OS的预言者。因此，一张新诺模图与一个C索引平等者被开发到0.757(95%CI，0.678-0.836)。在结论，迟模型与mCRPC预言了对待abiraterone的、化疗天真的病人的预后，并且我们开发了一张新诺模图与更少的参数预言这组病人的全面幸存。

简介：Injuryofankleisthemostcommoninathleticinjury.Becauseofanatomicparticu-larityofanklejoint,i.e.lateralmalleolusislongandthinandislocatedattheposteriorandlowerthanmedialmalleolus.Themedialmalleolusisbroadandflatandislocatedattheanterior.Lateralligamentisthinnerandweakerthanmedialligamentandthemusclegroupssupportingstrephexopodiaisfarinferi-ortothemusclegroupssupportingstrephenopodiainstrength,injuryofanklejointhappensmoreatinversionsprainandin-juryofanteriortalofibularligamentisinducedoften.Thus,rapidandeffectivetreatmentofanteriortalofibularligamentinjurycanelevatebetterathleticsofsportsman.Wheneverthediseasehappenedinstudentstoexercise,theauthorsoftenusedacupunctureofQiuxu（GB40）-through-Zhaohai（KI6）pointwithstrongstimulativemanipulation,whichcouldrelievemoreremakedlypainoftheanklejointcausedbyanteriortalofibularligamentinjuryasre-portedinthe

简介：Objective:Toanalyzelong-termoutcomeinsixtyleukemiapatientsreceivedallogeneichematopoieticstemcelltransplantation(allo-HSCT)followingbusulfanandcyclophosphamide(BU-CY2)between1994and2000.Methods:BU-CY2wasusedastheconditioningregimenandallo-HSCTwasperformedforallpatients.Allthepatientswerefollowed-upuntilAugust2001ordeath.Theleukemia-freesurvival,relapseandtransplant-relatedmortalitywerediscussed.Results:All60patientshadsustainedengraftment.AcuteGVHDoccurredin22outof60patients(36.7%),andtheincidenceofacuteGVHDwas48%inthepatientswithCML,30%inAMLand26.7%inALL.38patientsarestillaliveincontinuousremissionwithamedianfollow-upof30months(range12-84)and22patientshavedied.ThemaincausesofdeathwereacuteGVHDin3patients,CMV-IPin7patientsandrelapsein11patients,theremainingonediedofpulmonaryinfection.Among11patientswhodiedofrelapse,8patientswithALLrelapsedintheearlystageposttransplant(8/15,53.3%),relapsewasobservedintheremaining3patientswithAML,andhowever,norelapsewasobservedinCML.Theprobabilityofdisease-freesurvivalat3yearsforCML.AMLandALLpatientswas80%,70%and26.7%,respectively.Conclusion:ThisresultssuggeststhatBU-CY2isaneffectiveconditioningregimeninpatientswithAMLandCML,resultinginalowrelapserateandhighlong-termsurvivalrate,butnotaseffectiveinpatientswithALL,withahigherincidenceofrelapseandtherefore,notrecommendedforALLpatients.

简介：无

简介：AbstractBackground:This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice.Methods:The clinical data of patients with ER+ metastatic breast cancer treated with palbociclib were collected from the National Cancer Center database. The efficacy profile of palbociclib in this Han population was evaluated, especially for various combination regimens. The efficacy of palbociclib-based therapy in patients with prior everolimus treatment was also assessed.Results:A total of 186 patients from 89 cities in 18 provinces in China were enrolled. The median progression-free survival (PFS) was similar among different palbociclib-combined groups (P = 0.566): 10.0 months (95% confidence interval [CI] 3.8–16.1) in the +exemestane group, 9.7 months (95% CI 6.3–13.1) in the +letrozole group, 7.8 months (95% CI 5.5–10.2) in the +fulvestrant group, 7.2 months (95% CI 3.2–11.3) in the +toremifene group, and 6.1 months (95% CI 1.2–11.0) in the +anastrozole group. Thirty-four patients (18.3%) had received everolimus for their metastatic disease before the prescription of palbociclib. The disease control rate was significantly lower in patients who had received previous everolimus than in the everolimus-naïve group (50.0% vs. 82.2%, P < 0.001). Patients pre-treated with everolimus had significantly worse PFS than those in the everolimus-naïve group (3.4 months vs. 8.8 months, P = 0.001). After propensity score matching, patients pre-treated with everolimus had similar PFS (4.4 months, 95% CI 0.5–8.2) compared with everolimus-naïve patients (6.1 months, 95% CI 4.7–7.5, P = 0.439).Conclusions:Various palbociclib-based regimens have promising efficacy in ER+ metastatic breast cancer in real-world settings, even in patients who had been pre-treated with everolimus.

简介：AbstractBackground:Blood glucose control is closely related to type 2 diabetes mellitus (T2DM) prognosis. This multicenter study aimed to investigate blood glucose control among patients with insulin-treated T2DM in North China and explore the application value of combining an elastic network (EN) with a machine-learning algorithm to predict glycemic control.Methods:Basic information, biochemical indices, and diabetes-related data were collected via questionnaire from 2787 consecutive participants recruited from 27 centers in six cities between January 2016 and December 2017. An EN regression was used to address variable collinearity. Then, three common machine learning algorithms (random forest [RF], support vector machine [SVM], and back propagation artificial neural network [BP-ANN]) were used to simulate and predict blood glucose status. Additionally, a stepwise logistic regression was performed to compare the machine learning models.Results:The well-controlled blood glucose rate was 45.82% in North China. The multivariable analysis found that hypertension history, atherosclerotic cardiovascular disease history, exercise, and total cholesterol were protective factors in glycosylated hemoglobin (HbA1c) control, while central adiposity, family history, T2DM duration, complications, insulin dose, blood pressure, and hypertension were risk factors for elevated HbA1c. Before the dimensional reduction in the EN, the areas under the curve of RF, SVM, and BP were 0.73, 0.61, and 0.70, respectively, while these figures increased to 0.75, 0.72, and 0.72, respectively, after dimensional reduction. Moreover, the EN and machine learning models had higher sensitivity and accuracy than the logistic regression models (the sensitivity and accuracy of logistic were 0.52 and 0.56; RF: 0.79, 0.70; SVM: 0.84, 0.73; BP-ANN: 0.78, 0.73, respectively).Conclusions:More than half of T2DM patients in North China had poor glycemic control and were at a higher risk of developing diabetic complications. The EN and machine learning algorithms are alternative choices, in addition to the traditional logistic model, for building predictive models of blood glucose control in patients with T2DM.

简介：BackgroundH9c2celllineismononucleatedmyoblastderivedfromembryonicrathearttissue.ActivitiesofTGF-β1,MMP-2andMMP-9increaseinH9c2cellsaftertreatmentwithfibrosisstimuli.MicroRNA(miRNA),akindofendogenoussmallnon-codingRNA,participatesincardiacfibrosis.Inthepresentstudy,expressionsoffibrosis-relatedgenesandmicroRNAsinTGF-β1treatedH9c2cellswereinvestigated.MethodsExpressionsoffibrosis-associatedgenes,includingCol3a1,α-SMA,FN1,CTGFandTSP-1,weremeasuredinTGF-β1treatedH9c2cellsbyquantitativereversetranscriptionandPCR(qRTPCR).Levelofα-SMAinH9c2cellswasdemonstratedbyfluorescenceimmunohistochemistry(FIHC)assay.ExpressionsofmaturemiR-16,-21a,-29binH9c2cellsweredeterminedbyqRT-PCRassay.ActivationsofSmad3andNF-kBsignalinginTGF-β1-treatedH9c2cellswerestudiedbydualluciferaseassay.ExpressionsofCol3a1,α-SMA,FN1,CTGFandTSP-1weredetectedinH9c2cellswithadenovirus-mediatedoverexpressionofmiR-21a.ResultsqRT-PCRassayshowedthatα-SMA,FN1,CTGF,TSP-1,butnotCol3a1,wereup-regulatedinTGF-β1treatedH9c2cells.FIHCresultalsorevealedthatα-SMAwasincreasedinTGF-β1-treatedH9c2cells.Consistently,dualluciferaseassayshowedthatSmad3andNF-kBsignalingproteinswereactivatedinTGF-β1-treatedH9c2cells.miR-21a,butnotmiR-16and-29b,wassignificantlyup-regulated.Additionally,over-expressionofmiR-21asignificantlyincreasesmRNAexpressionsofα-SMA,FN1,CTGFandTSP-1inH9c2cells.ConclusionsMiR-21aisup-regulatedinTGF-β1treatedH9c2cells,andmaycontributetoup-regulationsoffibrosis-associatedgenes.

简介：Theworkistoexploretherelationshipbetweenthelevelsofcytokines(IL-1βandIL-6)inC57BL/6JmicetreatedwithMPTPandbrainlateralization.Byusingpawpreferencetest,right-pawed,left-pawedmicemodelswereestablished.Followingsingleinjectionof1-methyl-4-pheny1-2,3,6-tetrahydropyrid(MPTP)(40mg/kg)toimpairdopaminergicneuron,enzymelinkedimmunosorbentassay(ELISA)kitswereusedfordetectionofplasmalevelsofcytokines.TheresultsshowedthatinsalinetreatedC57BL/6Jmice(control),therewasnoobviousdifferenceobservedbetweenleft-pawedandright-pawedmiceinplasmalevelsofIL-1βandIL-6.InMPTPtreatedmice,therewasnodifferencebetweenlevelofIL-1βinleft-pawedmiceandthatinright-pawedonesinstatistics,thatis,theywereincreasedonday1andday3,butdecreasedonday6.TheplasmalevelofIL-6waslowerinleft-pawedthanthatinright-pawedmice(p＜0.005)afterMPTPtreatment.Onday1andday3,thelevelofIL-6wasalmostthesameascontrol;onday6,itwassignificantlyincreased,higherthanthatofcontrol(p＜0.001)inleft-pawedmice.Whileinright-pawedmice,onday1andday3,itwasnodifferentfromcontrol,too.Andonday6,itsignificantlyincreasedincomparedwithcontrol(p＜0.005).Inconclusion,thelevelofplasmaIL-6ofC57BL/6JmicetreatedwithMPTPincreased.ThevariationofIL-6wascorrelatedtobrainlateralization.

简介：AbstractBackground:Resting heart rate (RHR) is considered as a strong predictor of total mortality and hospitalization due to heart failure in hypertension patients. Bisoprolol fumarate, a second-generation beta-adrenoreceptor blockers (β-blocker) is commonly prescribed drug to manage hypertension. The present study was to retrospectively evaluate changes in the average RHR and its association with cardiovascular outcomes in bisoprolol-treated coronary artery disease (CAD) patients from the CAD treated with bisoprolol (BISO-CAD) study who had comorbid hypertension.Methods:We performed ad-hoc analysis for hypertension sub-group of the BISO-CAD study (n = 866), which was a phase IV, multination, multi-center, single-arm, observational study carried out from October 2011 to July 2015 across China, South Korea, and Vietnam. Multivariate regression analysis was used to identify factors associated with incidence of composite cardiac clinical outcome (CCCO), the results were presented as adjusted odds ratio (OR) along with 95% confidence interval (CI) and adjusted P value.Results:A total of 681 patients (mean age: 64.77 ± 10.33 years) with hypertension from BISO-CAD study were included in the analysis. Bisoprolol improved CCCOs in CAD patients with comorbid hypertension, with RHR <65 and <70 beats/min compared with RHR ≥65 and ≥75 beats/min, respectively, in the efficacy analysis (EA) set. In addition, it lowered RHR in both intent-to-treat (ITT) and EA groups after 6, 12, and 18 months of treatment. Further, RHR 70 to 74 beats/min resulted in significantly higher risk of CCCOs EA set of patients (adjusted OR: 4.34; 95% CI: 1.19-15.89; P = 0.03). Also, events of hospitalization due to acute coronary syndrome were higher when RHR 69 to 74 beats/min compared to RHR <69 beats/min in ITT patients.Conclusion:Bisoprolol can effectively reduce RHR in Asian CAD patients with comorbid hypertension and hence, improve CCCO without affecting their blood pressure.